Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN: brolucizumab versus aflibercept in macular edema secondary to central retinal vein occlusion
2018-001788-21Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal vein occlusion (CRVO) comparing Brolucizumab arm with Aflibercept arm (2 arms). Primary endpoint: Change from baseline in BCVA at Week 24. Started Mar 2019; status: terminated.
02
Drugs
brolucizumabaflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2018-001788-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001788-21.